Talks
chemo prevention and breast cancer
December 31, 2023
Share
treating micromets in breast cancer
December 31, 2023
Share
radiosensitization in breast cancer
December 31, 2023
Share
cdk46 in first line mbc and os
December 31, 2023
Share
tdxd and ild
December 31, 2023
Share
benefit of cdk46 in subtypes of er+
December 31, 2023
Share
extenet trial
November 19, 2023
Share
dato dxd in HR pos MBC
November 19, 2023
Share
ADCs in MBC
November 19, 2023
Share
capivasertib in HR pos MBC
November 19, 2023
Share
adj therapy in high risk her2 pos BC
November 19, 2023
Share
should we use IO in HR pos early BC?
November 19, 2023
Share
immunotherapy in HR+ early BC
November 19, 2023
Share
Second line HER2 pos MBC
October 1, 2023
Share
First line HER2 pos MBC
October 1, 2023
Share
secretory breast cancer
October 1, 2023
Share
Emerald trial
October 1, 2023
Share
Keynote 522
October 1, 2023
Share
Second line therapy in metastatic TNBC
October 1, 2023
Share
TILs in TNBC
October 1, 2023
Share
her2 mutations in breast cancer
August 15, 2023
Share
pdl1 in tnbc
August 15, 2023
Share
esr1 mutations
August 15, 2023
Share
first line therapy in met TNBC
July 31, 2023
Share
endocrine resistance.
July 31, 2023
Share
second line therapy in HR pos MBC
July 31, 2023
Share
neo chemo for tnbc
July 31, 2023
Share
therapy selections for neo HR pos BC
July 31, 2023
Share
neo adjuvant therapy in HR pos EBC
July 31, 2023
Share
pik3ca mutations in breast cancer.
June 29, 2023
Share
adj therapy for low risk her2 BC
June 29, 2023
Share
neo adjuvant therapy for her2 pos BC
June 29, 2023
Share
genetic testing for breast cancer
June 20, 2023
Share
sequencing cdk46
June 20, 2023
Share
defining triple negative breast cancer
May 30, 2023
Share
use of CDK4/6 inhibitors in early breast
May 27, 2023
Share
Close button
Why are you reporting this TALK?